Fig. 2
![Fig. 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40792-018-0479-3/MediaObjects/40792_2018_479_Fig2_HTML.png)
Abdominal computed tomography (CT) findings after four cycles of nivolumab. Abdominal enhanced-contrast CT revealed a marked reduction (by 55%) in liver metastases (arrows)
Abdominal computed tomography (CT) findings after four cycles of nivolumab. Abdominal enhanced-contrast CT revealed a marked reduction (by 55%) in liver metastases (arrows)